Paracetamol, a frequently used antipyretic and analgesic drug, has poor compression moldability owing to its low plasticity. In this study, new co-crystals of paracetamol (PCM) with caffeine (as a co-former) were prepared and delineated. Co-crystals exhibited improved compaction and mechanical behavior. A screening study was performed by utilizing a number of methods namely dry grinding, liquid assisted grinding (LAG), solvent evaporation (SE) and anti-solvent addition using various weight ratios of starting materials. LAG and SE were found successful in the screening study. Powders at 1:1 and 2:1 weight ratio of PCM/CAF by LAG and SE respectively resulted in the formation of co-crystals. Samples were characterized by PXRD, DSC and ATR-FTIR techniques. Compressional properties of PCM and developed co-crystals were analyzed by in-die heckle model. Mean yield pressure (Py), an inverse measure of plasticity, obtained from the heckle plots decreased significantly (p<0.05) for co-crystals than pure drug. Intrinsic dissolution profile of co-crystals showed up to 2.84 fold faster dissolution than PCM and physical mixtures in phosphate buffer pH 6.8 at 37 o C. In addition co-crystals formulated into tablets by direct compression method showed better mechanical properties like hardness and tensile strength. In vitro dissolution studies on tablets also showed enhanced dissolution profiles (~90-97%) in comparison to the tablets of PCM prepared by direct compression (~55%) and wet granulation (~85%) methods. In a single dose sheep model study co-crystals showed up to two fold increase in AUC and Cmax. A significant (p < 0.05) decrease in clearance as compared to pure drug was also recorded. In conclusion new co-crystals of PCM were successfully prepared with improved tabletability in-vitro and in-vivo profile. Enhancement in AUC and Cmax of PCM by cocrystallisation might suggest the dose reduction and avoidance of side effects.
INTRODUCTION
The successful development of a pharmaceutical dosage form requires adequate physical and mechanical properties of an active pharmaceutical ingredient (API). However, APIs with limited physical properties are becoming prevalent during the research and development process in pharmaceutical companies. Some compounds have less aqueous solubility and slow in vivo dissolution rate especially those belonging to the BCS class II (Low solubility and high permeability) and IV (Low solubility and low permeability) (1-4) others have high hygroscopicity and exhibit poor compaction properties. The properties e.g. solubility and dissolution rate are directly related to the bioavailability of the drugs, particularly when delivered via oral route (5, 6) .
On the other hand poor mechanical properties cause difficulties in the processing e.g. milling and compaction of a solid dosage form. Advancement in the pharmaceutical sciences has resulted in the establishment of a number of approaches to address these issues. These approaches include reduction of particle size (7), salt formation (8) , prodrug formation, complexation (9, 10) and liposomes for the delivery of lipophilic drugs (11) . Although these techniques are very effective in enhancing the oral bioavailability and processing properties of drugs, the success of these approaches is dependent on the specific physicochemical nature of the compound being studied.
For example salt formation which is only limited to ionizable compounds, complexation with disadvantages like low extent of interaction with complexing agent, increased toxicity, high cost and precipitation, prodrug which may not be adequately delivered at the site of action and particle size reduction limited by particle size induction and amorphization.
In recent years advancement in crystal engineering techniques like co-crystallization provides an alternative approach for improving various physicochemical properties of drug substances (12) (13) (14) (15) . Control of molecular packing within a crystal structure/lattice produces a solid that shows desirable characteristics including chemical stability (16, 17, 18) , solid state stability (19) , dissolution rate and bioavailability (20, 21) , and compaction behavior (22) (23) (24) . Furthermore, cocrystals may have an advantage over the high-energy crystal forms of superior thermodynamic stability in the solid-state (6, 25) . Therefore the interest in the co-crystallization has increased considerably over the past few years.
Pharmaceutical co-crystals are defined as supramolecular entities consisting of two or more molecular moieties held together by weak non-covalent and non-ionic intermolecular interactions (e.g. hydrogen bonding, p stacking, and VanderWaals forces) in which at least one or both constituents are active pharmaceutical agents i.e. two different molecules in a single crystalline lattice (26, 27) . Drugs having the ability to form hydrogen bonding with co-formers are considered as potential candidates for co-crystallization technique. Co-crystals of many pharmaceutical drugs are reported in literature e.g. carbamazepine, indomethacin, furosemide and piroxicam etc. (28) .
Recently various novel methods for the efficient production and monitoring of co-crystals have been proposed (29) .
Paracetamol (PCM) is widely used analgesic and antipyretic agent. It has low aqueous solubility and poor mechanical and compressional properties and hence has poor tabletability. Many studies have reported the problem of high capping which is related to stiff nature and a relatively high elastic deformation of PCM (30) . Due to these reasons, PCM tablets are being prepared using large amount of a binder to prevent chipping and disintegration of tablet dosage form (24) . Similarly a change in crystal structure e.g. polymorphsim or crystal habit has been shown to improve tableting properties of PCM (31) . Nevertheless lack of acidic or basic functional groups and presence of both proton donors (phenolic O-H and the amidic N-H groups) and acceptor (the amidic oxygen atom) make PCM a good model drug for co-crystal study. Caffeine (CAF) has already been successfully utilized as a co-former, and is a generally recognized as safe (GRAS) status compound. It has functional groups (keto-amide groups and basic nitrogen) which make it as a good candidate to form intermolecular hydrogen bonds in co-crystal formation ( Figure 1 
) (22).
Furthermore PCM is also available as fixed dose combination with caffeine to synergise the analgesic effect of PCM.
In the present work attempts were made to produce co-crystals of PCM with CAF as a co-former, these co-crystals has not been reported previously. Four different co-crystallisation methods were employed in the screening studies, with the aim to improve the compressional, mechanical behaviour and dissolution profile of the drug. Prepared co-crystals were evaluated for intrinsic dissolution rate and compaction behavior. Previously mechanical properties of co-crystals were determined by measuring the tensile strength only, however our study involves the heckle analysis, which give more thorough insight about the plasticity. Pharmacokinetic studies of newly formed co-crystals were also performed on sheep model in order to highlight the potential increase in oral bioavailability. Literature review has shown that only a few bioavailability studies have been reported for the co-crystals (19, 20) . To our knowledge, this is the first bioavailability study done one the PCM co-crystals. Lastly tablet formulations prepared from these co-crystals were also assessed for the pharmacotechnical properties.
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EXPERIMENTAL
Materials and Methods
PCM and CAF were obtained as gift samples from UNEXO Pharmaceuticals and Avicel PH 102 and magnesium stearate from Remington Pharmaceuticals, Lahore, Pakistan and were used as received. All organic solvents used were of HPLC or analytical grade. A phosphate buffer at pH 6.8 was prepared by mixing 250 ml of KH2PO4 (0.2 M) and 112 ml of NaOH (0.2 M) with final dilution to 1L with distilled water.
Screening of co-crystals
Various methods like mechanochemical (dry grinding, liquid assisted grinding (LAG)), solvent evaporation (SE) and anti-solvent addition (ASA) were used for the formation of co-crystals of PCM with CAF. 
Dry and liquid assisted grinding
Anti-solvent addition
Excess amount of PCM and CAF (1:1, 1:2 & 2:1 weight ratio) were added to 5 ml of methanol and acetone separately to make turbid solutions, stirred for 15 minutes and filtered through Whatman filter paper. Distilled water (2 ml) (as an anti-solvent (32)) was added to the filtrate to induce precipitation. Samples were then centrifuged at 3000 rpm for 20 minutes to allow solids to deposit out.
Characterization
The pure drugs and co-crystals prepared by the above methods were investigated by DSC, PXRD, ATR-FTIR and Intrinsic dissolution rate (IDR) studies.
Differential scanning calorimetry (DSC)
DSC studies were performed using a TA instrument (model Q 600, USA). Samples (2−5 mg) contained in alumina pan with an empty pan as a reference were analyzed from room temperature (25± 2 °C ) to 300 °C with a constant heating rate (10 °C /min) under a nitrogen purge (100 ml/min).
Powder X-Ray Diffraction (PXRD)
PXRD patterns were obtained for PCM, CAF and co-crystals synthesized by various methods.
Powder samples were used as such without any pre treatment. PXRD data were collected on a Pan
Analytical diffractometer XPERT-PRO (operating at 40 kV, 40 mA), using Cu-Kα radiation (λ = 1.5418 Å) with a position sensitive detector. Diffraction data were collected in the range 2θ = 5- 
ATR-FTIR spectroscopy
Fourier Transform Infrared (FTIR) spectra were recorded for the PCM, CAF and synthesized cocrystals using FTIR spectrophotometer (Alpha-P Bruker, Germany) equipped with an ATR unit across the range of 4000-400 cm -1 . 
Scanning Electron Microscopy (SEM)
Drug content analysis
A stock solution containing 1 mg/mL of pure drug was prepared by dissolving 100 mg of PCM in 100 mL of phosphate buffer (pH 6.8) using a volumetric flask. The standard stock solution was further diluted to obtain a working standard solution of 100 µg/ml. Working standard solution was then diluted with phosphate buffer (pH 6.8) to obtain a series of solutions with the concentration range of 2-16 µg/ml. A calibration curve for PCM was prepared by measuring the absorbance at the λmax of 243 nm. Statistical parameters like slope, intercept and coefficient of correlation were determined to model the linearity of absorbance data.
For drug content analysis, each of the co-crystal samples was accurately weighed (10 mg) and dissolved in phosphate buffer pH 6.8 to give final concentration of 10µg/ml. The drug content was calculated from the calibration curve.
Intrinsic dissolution studies
The intrinsic dissolution rate (IDR) of pure drug, physical mixtures and co-crystals was determined by rotating disc method using a constant surface area of 13 mm in diameter. Discs were prepared by compressing 300 mg of powder samples by a hydraulic press (Carver, USA) at a pressure of ~5000 psi for 60-90 seconds. The compacts were coated with hard paraffin leaving a surface available for dissolution (33, 34) and then placed to the base of the dissolution vessel.
The dissolution studies, performed in triplicate, were carried out in phosphate buffer pH 6.8
(volume: 500 ml, temperature: 37 °C) in a paddle apparatus (Apparatus 2, USP) at a rotation speed of 50 rpm. Aliquots (5 ml) were withdrawn at time intervals of 2, 4, 6, 8, 10, 14, 18 and 22 min.
Samples were filtered through 0.45 μm filters and analyzed at 243 nm. Dissolution medium was replenished with the same volume (5ml) of blank (phosphate buffer pH 6.8) in order to maintain the sink conditions. IDR was determined by plotting the cumulative amount of drug dissolved per surface area (mg/cm 2 ) versus time (min).
Compressional behavior
In-die heckle model (35) for powder deformation under pressure (equation 1) was used to study the compressional behavior of pure PCM and prepared co-crystals powders. Bulk density of each powder was determined by the standard method. Each of the material (300 mg) was individually compacted under compressional force between 2 and 14 MPa using a hydraulic press (Carver, USA) equipped with flat faced dies 13 mm in diameter. Volume reduction was measured at each compaction pressure used.
Where, D is the relative density of the compact at applied pressure P,and the constant K is a measure of the plasticity of the compressed material. Integration of equation 1 gives equation 2.
A plot was drawn between Ln (1)/1-D and compaction pressure (P) for each powder. A is the intercept of the extrapolated linear region of the curve. Mean yield pressure (P y), a measure of the material ' s resistance for deformation (36) , was obtained from the reciprocal of the slope (K) of the linear portion of the heckle plot. The higher the value of slope K is, more plastic is the material.
Preparation of Tablets
Direct compression method was used to prepare tablets from all co-crystal powders. For this purpose co-crystal equivalent to 250 mg of PCM was blended with Avicel PH 102 (20 % of the weight of co-crystal) and magnesium stearate (0.5 % of the weight of co-crystal) for about 15 min.
The mass was then compressed using a hydraulic press fitted with 13 mm diameter die. As pure PCM cannot be directly compressed due to poor compressional properties, it was moistened with small amount of water and then dried at 50 were prepared following the same procedure. Tablets of pure PCM (F2) (250 mg equivalent) were also prepared by the standard wet granulation (WG) method using starch paste (10 % of the weight of PCM) as a binder and dry starch as disintegrating agent (10 % of the weight of PCM).
Evaluation of tablets
All the prepared tablets were evaluated for hardness, tensile strength, disintegration time and in vitro dissolution study. Hardness was determined using Pharmatron Multitest 50H and expressed in newton. Tensile strength, σ, in MPa was determined by diametral compression test (37) and calculated by using equation 3.
Where F is the breaking force (N), D is the tablet diameter (m), and T is the thickness of tablet (m). Disintegration test was carried out by tablet disintegration test apparatus using distilled water at 37 °C.
In-vitro dissolution study
Dissolution studies for all prepared tablets were performed using phosphate buffer pH 6.8 (volume: 900 ml, temperature: 37 °C) as a dissolution medium in a paddle apparatus (Apparatus 2, USP) at a rotation speed of 50 rpm. Aliquot (5 ml) was withdrawn at time intervals of 3, 6, 9, 12, 17, 22, 27 and 32 minutes and replaced with fresh dissolution medium in order to maintain the sink conditions. These samples were analyzed for PCM concentration by UV Visible spectrophotometer at 243 nm. All the measurements were done in triplicate. Percent drug release was determined from the calibration curve (R 2 = 0.996). The drug release data was also fitted to various kinetic models such as zero order, first order, and Higuchi, Korsmeyer-Peppas and HixonCrowell model using DD solver (38) . 
In-vivo studies in sheep
RESULTS AND DISCUSSION
Co-crystal screening was carried out by four different methods as described in Table 1 . Formation of co-crystals were recorded by difference in melting points and PXRD patterns from the individual components. PCM-CAF co crystals were successfully prepared by LAG and SE methods. In LAG, mixtures of PCM and CAF at weight ratio 1:1 with solvents S1, S2 and S3 were resulted in co-crystals (PXRD pattern were different from either of the two starting materials, Figure 2 ). In SE method the solution of PCM and CAF in weight ratio 2:1 using solvent systems (S1 and S2) resulted in formation of co-crystals. All the other mixtures/solutions in the screening study produced intact crystals of the individual components i.e. PCM and CAF.
Place table 1 
Intrinsic dissolution rate (IDR)
Intrinsic dissolution rate (IDR) method was employed as it affords advantages over other powder dissolution methods because the exposed area of the disk is constant and thus dissolution variability can be minimized. Intrinsic dissolution profiles of the prepared co-crystals compared with pure drug are shown in Figure 5 . indicate the stability of prepared co-crystals to prevent dissociation of drug and co-former from each other and achieve the solubility and dissolution advantages of co-crystals (42) .
IDR is the dissolution rate that is greatly influenced by the intrinsic factors especially the crystal habit and particle size distribution. The variation among the IDR values of co-crystals can be explained by the fact that the powders prepared by the two different methods (LAG and SE) have different particle size distribution and shapes. This is evident from the SEM images of these samples as shown in Figure 6 . Mechanochemical method (LAG) produced fine powders with high compressibility index (~ 31.12 %). On the other hand the powder samples prepared by SE method show larger particles with low compressibility index value of ~ 20.55 %. Owing to this fact more compact IDR discs were prepared from LAG samples which resulted in lower values of IDR as compared to samples of SE. This is also evident from the higher breaking force (hardness) of the tablet formulations prepared from A, B and C samples as compared to D and E samples (Table 3) .
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Compressional and mechanical properties
Poor compressibility of PCM due to low plasticity is always a problem for the formulation scientists. To overcome this problem, PCM is normally tableted by wet granulation (WG) method, which is a time consuming and laborious procedure and required a large amount of excipients to be added to the formulation. Development of crystal structures, which provide large interparticulate bonding area and plasticity, has been proposed as a strategy to improve the tensile strength of materials (43) . In the present study heckle plots were drawn for pure PCM and cocrystals powders to assess the plastic behavior induced by co-crystallization ( Figure 7 ). Co-crystals showed improved compaction and hence high plasticity. This was shown by low Py (mean yield pressure) value for co-crystals as compared to pure drug. Py recorded for PCM was 133.33 MPa.
The same parameter for formed co-crystals A, B, C, D and E was significantly decreased i-e. 33.03, 80, 28.65, 33.03 and 47.62 MPa respectively. The ranking of the Py values was C<A&D<E<B<PCM (Table 3) . These values were calculated from the region of heckle plots showing the highest correlation coefficient for linearity of > 0.989 for all the powder samples. The yield pressure, Py, is the stress at which particle deformation is initiated reflecting the deformation of the particles during compression (44) . Difference in compression properties among co-crystals produced by LAG and SE is due to dissimilar crystal plasticity which may result from unique molecular packing features in the respective crystal lattices. Mechanochemically synthesized cocrystals are more plastic and have high tensile strength as evident from their low mean yield pressure (Py) value (33.03 & 28.65). Previous literature also confirms mechanochemical synthesis as an efficient approach to produce plastic and compressible forms of PCM using oxalic acid, phenazine, theophylline and naphthalene as coformers (24) .
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Results from the compression data indicate that co-crystals can easily be formulated, by direct compression with adequate hardness to the tablet dosage form without adding any binder. The tensile strength higher than 3MPa was exhibited by tablets based on co-crystals prepared by LAG (FA, FB and FC) while the tablets based on co-crystals prepared by SE were in the vicinity of >1.8
MPa (Table 3 ). This suggests that mechanochemical methods of co-crystallization are more suitable to improve the pharmacotechnical properties of PCM.
Place table 3 here
In-Vitro drug release study of Tablets
Various tablet formulations prepared from pure drug, physical mixtures and co-crystals were subjected to the in vitro dissolution studies for the release of PCM. Direct compression method was employed for the co-crystals formulations (FA, FB, FC, FD and FE). However for pure drug, both liquid assisted direct compression (F1) and wet granulation method (F2) were used. Figure 8 shows comparison of dissolution profiles of these formulations. All the co-crystals formulations showed 90 -97 % release within 20 min. This was greater than corresponding physical mixtures (55 %), F1 (72 %) and F2 (85 %).
As already explained before that the LAG method of co-crystallization produce powders with a large surface area so mechanochemical synthesis based formulations were expected to give better dissolution profiles as compared to SE based formulations. This can also be confirmed by SEM Release kinetics results show that the release of PCM from formulations F1 and F2 followed
Korsemeyer-Peppas and Hixon-Crowell models, respectively. While dissolution data of the cocrystal formulations FA &FB followed Korsemeyer-Peppas and formulations FC, FD & FE followed Hixon-Crowell model for drug release (Table 4) . Moreover all the formulations showed non-Fickian (anomalous) drug release (0.45 ≤ ≤0.89).
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In-Vivo performance of PCM and co-crystals
Place figure 9 here
Powder co-crystal samples from each of the successful method showing higher IDR i.e. C and E were selected for oral bioavailability studies. Figure 9 shows the plasma concentration profiles for PCM and selected co-crystals. The mean pharmacokinetic metrics calculated from the sheep model study data are presented in Table 5 . The mean AUC values were 11.22 and 9.36 µgh/ml for cocrystals C and E, respectively, which were almost two times enhanced that of PCM (5.02 µgh/ml).
Cmax of C (2.40 µg/ml) and E (1.72 µg/ml) was 2.45 and 1.80 fold that of PCM (0.98 µg/ml) without any change in the time for peak concentration. The increase in peak concentration for cocrystals may be attributed to decreased elimination because of higher accumulation of drug. Mean residence time of the co-crystals was observed to be high with low clearance values suggesting enhanced absorption window. Co-crystals also showed more than two times enhancement in the relative oral bioavailability than the pure PCM. The bioavailability of both co-crystals was significantly better than pure drug based on One way ANOVA followed by Tukey's post hoc test (p<0.05).
Difference in in-vivo behaviour between the co-crystal samples prepared by two methods can be attributed to the dissimilarity in the physicochemical properties especially dissolution rate ( Figure   8 ). Physiological variations among the subjects may also contribute to these small differences.
However in comparison with each other (C with E and E with C) the pharmacokinetic parameters Cmax and AUC were insignificant (p> 0.05).
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